[Corrigendum] Fully human VEGFR2 monoclonal antibody BC001 attenuates tumor angiogenesis and inhibits tumor growth

Int J Oncol. 2023 Dec;63(6):135. doi: 10.3892/ijo.2023.5583. Epub 2023 Oct 27.ABSTRACTSubsequently to the publication of the above paper, an interested reader drew to the authors' attention that, for the scratch wound assay experiments shown in Fig. 1 on p. 2413, the panels showing the '0 h' experiments for the respective incubations with VEGF or BC001 were apparently identical. The authors were able to re‑examine their original data files, and realized that this figure had been inadverently assembled incorrectly. The revised version of Fig. 1, containing the correct data for the '0 h / BC001' panel, is shown below. Note that the revisions made to this figure do not affect the overall conclusions reported in the paper. The authors are grateful to the Editor of International Journal of Oncology for allowing them the opportunity to publish this Corrigendum, and apologize to the readership for any inconvenience caused. [International Journal of Oncology 45: 2411‑2420, 2014; DOI: 10.3892/ijo.2014.2690].PMID:37888731 | DOI:10.3892/ijo.2023.5583
Source: International Journal of Oncology - Category: Cancer & Oncology Authors: Source Type: research